Summary by Moomoo AI
AstraZeneca reported robust H1 2024 results, with Total Revenue up 18% to $25.6B and Core EPS up 5% to $4.03. Strong underlying growth led to an upgrade in FY 2024 guidance, with Total Revenue and Core EPS now expected to increase by a mid-teens percentage at CER.Product Sales grew 18%, driven by Oncology (+22%), CVRM (+22%), and R&I (+22%). Key growth drivers included Farxiga, Tagrisso, Imfinzi, and Ultomiris. The company highlighted positive data readouts for several high-priority medicines and continued progress in disruptive technologies like antibody drug conjugates and cell therapies.AstraZeneca completed strategic acquisitions of Gracell Biotechnologies and Fusion Pharmaceuticals, enhancing its cell therapy and radioconjugate capabilities. The company also announced plans for a $1.5B ADC manufacturing facility in Singapore. An interim dividend of $1.00 per share was declared, up 7 cents from the previous year.